NomosLogic Inc

06/07/2026

NomosLogic multi-omics

06/07/2026

Visit: https://lite.nomoslogic.com

06/06/2026

Your doctor looks at your blood work. A separate specialist looks at your imaging. A genetic counselor might look at your DNA, if anyone orders the test. A pharmacist fills the prescription without seeing any of it.

Nobody is looking at all of it together.

That is the problem multi-omic medicine solves. And it is what NomosLogic does.

Multi-omics means combining your genetic data, your lab results, your biomarkers, and your clinical history into one analysis instead of keeping them in separate silos. Because your body does not operate in silos. Your genes affect how you metabolize your medications. Your medications affect your lab results. Your lab results tell a different story when your doctor knows the genetic architecture underneath them.

Here is a real example from my own case. My blood work showed low iron. A standard doctor would prescribe iron supplements and move on. But when my genetic data was analyzed alongside my labs, it revealed six different genes working together to affect how my body absorbs, transports, and uses iron. The iron deficiency was not a simple nutritional problem. It was a multi-gene pattern that standard medicine had no way to see because nobody was looking at the genetics and the blood work at the same time.

That is what NomosLogic's TRINITY platform does. It takes your existing DNA data and fuses it with your lab results to find patterns and connections that no single test can reveal on its own.

Your DNA affects which medications work for you and which ones could be dangerous. It affects how your body processes hormones, cholesterol, blood sugar, and nutrients. It affects how you respond to supplements. None of that information shows up on a standard lab panel. And none of it shows up on a consumer DNA report from 23andMe or AncestryDNA.

But when you combine them, the picture changes completely.

If you have ever wondered why a medication did not work for you, why your labs look "normal" but you still feel off, why the same treatment works for someone else but not for you, the answer is almost certainly in the space between your DNA and your blood work. The space nobody has been looking at.

NomosLogic looks at that space. In under three minutes. From a DNA file you already have.

lite.nomoslogic.com

06/04/2026

Let's talk about a dirty little secret in genomics: the "Tower of Babel" problem. We have dozens of brilliant systems, from EMRs to lab information systems to sequencing platforms, and almost none of them speak the same language. A gene variant might be named one thing in ClinVar, another in a proprietary database, and something else entirely in a research paper.

The result is a staggering amount of friction and manual work. Analysts spend countless hours, sometimes weeks, just trying to reconcile nomenclature. It’s like trying to assemble a puzzle where every piece is from a different box. This isn't just inefficient; it's dangerous. A missed mapping can lead to a misinterpretation, which can lead to a catastrophic clinical outcome.

We knew this had to be solved at the root. So we built the Rosetta Stone for genomics: the Hardy Bridge.

This isn't just a database; it's a dynamic, semantic translation layer. With over 496,805 nomenclature mappings (and growing daily), it connects the dots across more than 40 disparate systems. When data enters the NomosLogic OS, Hardy Bridge instantly harmonizes it into a single, unified language. What used to take a PhD-level analyst 2-4 weeks of painstaking detective work now happens in a fraction of a second, as part of our sub-130-second variant resolution process.

This seamless interoperability is the backbone of our LaaS (Logic-as-a-Service) architecture. It means our partners don't have to rip and replace their existing systems. They simply plug into our OS, and we handle the translation. This is the unglamorous, foundational work that unlocks everything else. It’s the plumbing that makes the entire skyscraper of precision medicine possible.

06/04/2026

What if we could map the ghost of evolutionary pressure onto a modern clinical trial? The “ancestral adaptation thesis” posits that many modern diseases are mismatches between our ancient biology and our current environment. Understanding this requires a new class of computational tools.

Our PROTEUS engine is built for this purpose: simulating evolutionary and selective pressures to uncover novel biological insights. By analyzing how genetic variants have behaved over millennia, we can better predict their function today. This isn't just about interpreting a single variant; it's about understanding the deep, causal architecture of disease and de-risking the next generation of therapeutics.

06/01/2026

You took a DNA test a few years ago. 23andMe. AncestryDNA. Maybe both.

You got your ancestry breakdown. Maybe some fun trait reports. Then the file went into a drawer, a cloud account, or a folder on your laptop. Forgotten.

That file contains over 600,000 data points about your body. Not your heritage. Your health.

It contains information about how you metabolize medications. Which drugs work for your specific genetics and which ones don't. Which supplements your body can actually process and which ones are doing nothing. Whether you carry variants that make certain common prescriptions dangerous at standard doses.

Nobody has ever read that part of your file. Not your doctor. Not 23andMe. Nobody.

I know because I was in the same position. My name is Matt Hardy. I'm 50 years old. I took a DNA test in 2017 and forgot about it. Eight years later, I ran that same file through the platform I built, and it found two variants that make common drugs potentially lethal for me at standard doses. One is a chemotherapy drug. One is an immunosuppressant. Neither was ever flagged by any doctor in my entire life.

Learn your biology: https://lite.nomoslogic.com

Dendrite Lite — Discover what your DNA says about your health. Personalized genetic health reports by NomosLogic.

05/28/2026

BIO2026 is already shaping up to be an important week for NomosLogic and molecular medicine.

We are looking forward to the partner meetings already on the calendar, and we are opening a limited number of additional meeting slots for organizations that want to work with us around:

Deterministic Molecular Medicine Infrastructure

NomosLogic is built to turn molecular data into governed, reproducible, clinically useful and commercially actionable infrastructure.

We are interested in meeting with:

Clinical point of care organizations:
Hospitals, physicians, care networks, specialty clinics and wellness clinics looking to bring deterministic molecular insight into care delivery.

Payers:
Organizations working on utilization, pharmacogenomics, population risk, evidence governance and smarter clinical decision infrastructure.

Pharma and biotech:
Teams focused on drug discovery, target prioritization, biomarker strategy, trial stratification and understanding which biological contributors are primary, which are compensatory and which combinations expose system limits.

Sequencing companies, diagnostics groups and labs:
Partners who want to move beyond raw data and static reports into interpretation, reanalysis, evidence governance and scalable molecular medicine infrastructure.

Consumer genomics and health platforms:
Companies that want to turn existing DNA data into a more useful, longitudinal and clinically relevant substrate.

Investors:
Groups looking for category defining infrastructure at the intersection of genomics, clinical systems, pharma, payers, diagnostics and consumer molecular medicine.

The goal is simple: meet the right partners, build the right relationships and bring deterministic molecular medicine infrastructure into the systems where it can create the most value.

Our BIO2026 meeting availability is filling quickly. If molecular data matters to your organization, this is a good time to connect.

For partnership opportunities and to schedule with us at BIO2026:

Founder and CEO:
[email protected]

SVP of Business Development:
[email protected]

www.nomoslogic.com

You can also send Jai or myself a direct message, we look forward to seeing you next month.

05/28/2026

We're revolutionizing the way you take control of your health with a bold new look for Dendrite Lite, our clinically validated consumer product, featuring enhanced interactions, stunning design, and the same trusted, deterministic results. The new look launches soon.

Learn more about NomosLogic and molecular medicine infrastructure at www.nomoslogic.com

For Consumers:
Visit https://lite.NomosLogic.com to sign up now
Use code: FREE500 before it is gone. This code is being used fast and the opportunity will be gone.

05/25/2026

The calendar at BIO 2026 is already filling. Here's where NomosLogic plugs in.

NomosLogic is deterministic molecular medicine infrastructure. The foundational layer that turns molecular complexity into clinical clarity and commercial value.

San Diego Convention Center. June 22 to 25.

We want working conversations with partners across:

▸ Clinical Point of Care

▸ Consumer Genomics

▸ Payer Infrastructure

▸ Pharma Drug Discovery

▸ Sequencing Companies

▸ Diagnostics and Labs

▸ Category-scale Investors

If you operate in any of these surfaces and want to talk about where deterministic infrastructure plugs into your roadmap, DM me to lock 30 minutes during the conference.

Partnerships and BD: [email protected]

Strategic and CEO-level: [email protected]

hashtag

05/25/2026

NomosLogic Inc and I will be at BIO International 2026.
NomosLogic is deterministic molecular medicine infrastructure.

The platform turns genomic and multi-omic data into reproducible, auditable, clinically usable outputs and pharmacogenomics. One layer, four ex*****on domains: clinical genomics, consumer genomics, payer infrastructure, and pharma research.
learn more about us at: https://www.nomoslogic.com

In production today:
▸ Deterministic genome resolution in under 30 seconds ▸ Multi-omic fusion in under 90 seconds ▸ 1.26M+ structured Clinical Logic Objects ▸ 497K+ Hardy Bridge variant mappings ▸ 20.2M+ anchored molecular reference assets ▸ 608+ FDA drug-gene mandates

If you run pharma R&D, a health system, a payer organization, or a fund covering this category, DM me. I'll lock 30 minutes during the conference. Same input, same output. Findings trace to source. Logic is governed and versioned.

The calendar fills fast.

Governed, reproducible, clinically defensible intelligence for health systems, consumer genomics, payers, and pharma.